Compare ADCT & QNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADCT | QNC |
|---|---|---|
| Founded | 2011 | 2007 |
| Country | Switzerland | Canada |
| Employees | N/A | 5 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 431.2M | 434.7M |
| IPO Year | 2019 | 2026 |
| Metric | ADCT | QNC |
|---|---|---|
| Price | $0.95 | $3.07 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $7.75 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 779.8K |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.86 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $81,357,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $66.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.85 | N/A |
| 52 Week Low | $0.78 | $1.90 |
| 52 Week High | $4.98 | $3.51 |
| Indicator | ADCT | QNC |
|---|---|---|
| Relative Strength Index (RSI) | 11.51 | 50.85 |
| Support Level | N/A | $2.58 |
| Resistance Level | $4.77 | N/A |
| Average True Range (ATR) | 0.19 | 0.26 |
| MACD | -0.26 | -0.01 |
| Stochastic Oscillator | 5.36 | 49.44 |
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
Quantum eMotion Inc is dedicated to developing of a new generation of quantum-safe encryption for the quantum computing age. It is a developer of a new generation of cryptographic solutions under the acquisition of licenses. It allows clients and partners to develop secure quantum-safe encryption that can protect anything from consumer and enterprise devices like mobile phones, computers, the Internet of Things, and networking equipment to demanding cloud-based applications, servers, and military devices.